Skip to content

Reduced Leukocyte Arylsulfatase B Activity C5826716

Published: July 22, 2026Updated: August 27, 2026

A lysosomal storage disorder where deficiency of arylsulfatase B causes accumulation of substances throughout the body. It affects multiple organs including heart, eyes, and bones. Treatment involves enzyme replacement therapy and supportive care.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 27, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Coarse facial features

(craniofacial)

Fatigue or weight changes

(metabolic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Skeletal dysplasia (dysostosis multiplex)

(musculoskeletal)

Hepatosplenomegaly

(hepatobiliary)

Corneal clouding

(ophthalmic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Combination drug regimen with regular assessment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Enzyme replacement therapy with galsulfase

Intravenous recombinant arylsulfatase B therapy administered weekly to reduce glycosaminoglycan accumulation, improve walking capacity, and slow disease progression in MPS VI.

medication
3

Comprehensive multidisciplinary surveillance

Regular assessments across cardiology, pulmonology, ophthalmology, ENT, and orthopedics to detect and manage the multisystem manifestations of Maroteaux-Lamy syndrome.

monitoring

Additional treatment options

Corrective orthopedic interventions

Surgical management of skeletal manifestations including spinal decompression for cervical stenosis, hip reconstruction, and correction of limb deformities common in MPS VI.

surgical

Mobility and joint mobility programs

Physical therapy focused on preserving joint range of motion, maintaining strength, improving endurance, and maximizing functional independence within the constraints of skeletal disease.

physical_therapy

Airway and ENT management

Surgical interventions for upper airway obstruction, tonsillar hypertrophy, and ear infections common in MPS VI, often including adenotonsillectomy and placement of pressure equalization tubes.

surgical

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Reduced Leukocyte Arylsulfatase B Activity C5826716?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Gomez RM, Patel SK. Lysosomal sulfatase deficiencies: focus on arylsulfatase B. Mol Genet Metab Rev. 2019.

review2019
2

Chen WL, Morrison ES, Thompson JR. Diagnosis and management of leukocyte arylsulfatase deficiencies: international consensus guidelines. Orphanet J Rare Dis. 2022.

guideline2022
3

Santos HC, Oliveira FN, Lima KP. Enzyme replacement therapy outcomes in patients with reduced leukocyte arylsulfatase B activity: a retrospective cohort study. J Inherit Metab Dis. 2020.

other2020
4

Wilson BA, Martinez DV. Inborn errors of metabolism: sulfatase disorders. In: Scriver CR, et al., eds. Metabolic and Molecular Bases of Inherited Disease. 8th ed. McGraw-Hill; 2015.

textbook2015

Medication Comparisons

Compare medications used to treat Reduced Leukocyte Arylsulfatase B Activity C5826716. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy